JP7789662B2 - Ｍｔａ協働ｐｒｍｔ５阻害剤 - Google Patents

Ｍｔａ協働ｐｒｍｔ５阻害剤

Info

Publication number
JP7789662B2
JP7789662B2 JP2022516295A JP2022516295A JP7789662B2 JP 7789662 B2 JP7789662 B2 JP 7789662B2 JP 2022516295 A JP2022516295 A JP 2022516295A JP 2022516295 A JP2022516295 A JP 2022516295A JP 7789662 B2 JP7789662 B2 JP 7789662B2
Authority
JP
Japan
Prior art keywords
mmol
equiv
alkyl
mixture
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516295A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021050915A5 (https=
JP2022548255A (ja
JP2022548255A5 (https=
Inventor
ボビンスキー、トーマス、ピー．
スミス、クリストファー、ロナルド
マルクス、マシュー、アーノルド
ケッチャム、ジョン、マイケル
バーンズ、アーロン、クレイグ
ロウソン、ジョン、デイヴィッド
クーリク、スヴィトラナ
ケーラー、ジョン
イヴェタック、アンソニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of JP2022548255A publication Critical patent/JP2022548255A/ja
Publication of JPWO2021050915A5 publication Critical patent/JPWO2021050915A5/ja
Publication of JP2022548255A5 publication Critical patent/JP2022548255A5/ja
Application granted granted Critical
Publication of JP7789662B2 publication Critical patent/JP7789662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022516295A 2019-09-12 2020-09-11 Ｍｔａ協働ｐｒｍｔ５阻害剤 Active JP7789662B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962899575P 2019-09-12 2019-09-12
US62/899,575 2019-09-12
US201962942833P 2019-12-03 2019-12-03
US62/942,833 2019-12-03
US202062961371P 2020-01-15 2020-01-15
US62/961,371 2020-01-15
US202062994927P 2020-03-26 2020-03-26
US62/994,927 2020-03-26
US202063060261P 2020-08-03 2020-08-03
US63/060,261 2020-08-03
PCT/US2020/050457 WO2021050915A1 (en) 2019-09-12 2020-09-11 Mta-cooperative prmt5 inhibitors

Publications (4)

Publication Number Publication Date
JP2022548255A JP2022548255A (ja) 2022-11-17
JPWO2021050915A5 JPWO2021050915A5 (https=) 2023-09-13
JP2022548255A5 JP2022548255A5 (https=) 2023-09-13
JP7789662B2 true JP7789662B2 (ja) 2025-12-22

Family

ID=72659905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516295A Active JP7789662B2 (ja) 2019-09-12 2020-09-11 Ｍｔａ協働ｐｒｍｔ５阻害剤

Country Status (17)

Country Link
US (3) US11492351B2 (https=)
EP (1) EP4028388A1 (https=)
JP (1) JP7789662B2 (https=)
KR (1) KR20220083691A (https=)
CN (2) CN114728912A (https=)
AU (1) AU2020345899B2 (https=)
BR (1) BR112022004248A2 (https=)
CA (1) CA3150515A1 (https=)
CL (1) CL2022000603A1 (https=)
CO (1) CO2022004513A2 (https=)
IL (2) IL290341B2 (https=)
MX (1) MX2022002938A (https=)
NO (1) NO20220309A1 (https=)
PH (1) PH12022550399A1 (https=)
SA (1) SA522431915B1 (https=)
TW (1) TW202122387A (https=)
WO (1) WO2021050915A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202122387A (zh) * 2019-09-12 2021-06-16 美商米瑞替療法公司 Mta協同性之prmt5抑制劑
US20240208912A1 (en) * 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors
IL307393A (en) * 2021-04-08 2023-12-01 Mirati Therapeutics Inc Combination therapies used in PRMT5 inhibitors to treat cancer
IL307392A (en) * 2021-04-08 2023-12-01 Mirati Therapeutics Inc Combination therapies with PRMT5 inhibitors for cancer treatment
EP4347569A4 (en) * 2021-06-02 2025-03-26 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
EP4412607A1 (en) 2021-10-06 2024-08-14 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors for the treatment of cancer
IL311707A (en) 2021-10-06 2024-05-01 Mirati Therapeutics Inc Methods for the separation of enantiomers
US20260109709A1 (en) 2021-11-05 2026-04-23 Mirati Therapeutics, Inc. 2-amino imidazole derivatives as prmt5 inhibitors
WO2023098439A1 (zh) * 2021-11-30 2023-06-08 上海和誉生物医药科技有限公司 一种吡唑衍生物，其制备方法和在药学上的应用
EP4458812A1 (en) * 2021-12-27 2024-11-06 Medshine Discovery Inc. Pyrazole-1(2h)-phthalazinone compound and application thereof
CN114315735B (zh) * 2021-12-29 2023-08-01 广州中医药大学(广州中医药研究院) 一种鲁米诺酯化衍生物及其制备方法与应用
CN116903611A (zh) * 2022-01-26 2023-10-20 上海优理惠生医药有限公司 一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用
EP4493555A4 (en) * 2022-03-15 2026-03-25 Beone Medicines I Gmbh 4-(AMINOMETHYL)-6-(1-METHYL-1H-PYRAZOL-4-YL)ISOQUINOLIN-1(2H)-ONE DERIVATIVES USED AS PRMT5 INHIBITORS COOPERATE WITH MTA
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
CN117843634A (zh) * 2022-05-24 2024-04-09 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
CN116178347B (zh) * 2022-06-29 2025-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
EP4574816A4 (en) 2022-07-07 2026-01-14 Xizang Haisco Pharmaceutical Co Ltd HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5 - MTA AND ITS USE
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
CN119585261A (zh) * 2022-08-02 2025-03-07 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
CN119730853A (zh) 2022-08-15 2025-03-28 阿斯利康(瑞典)有限公司 用于治疗癌症的mta协同prmt5抑制剂
CN119836290A (zh) 2022-09-01 2025-04-15 米拉蒂治疗公司 使用prmt5抑制剂和bcl-2家族抑制剂治疗癌症的组合疗法
WO2024091551A1 (en) * 2022-10-25 2024-05-02 Tango Therapeutics, Inc. Crystalline forms, pharmaceutical compositions and methods of use thereof
EP4628483A1 (en) * 2022-11-29 2025-10-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Dihydrophthalazine-containing compound
WO2024173215A1 (en) 2023-02-13 2024-08-22 Mirati Therapeutics, Inc. Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1h- pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
US20240270719A1 (en) 2023-02-13 2024-08-15 Mirati Therapeutics, Inc. Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
EP4665722A1 (en) 2023-02-13 2025-12-24 Mirati Therapeutics, Inc. Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
KR102818470B1 (ko) * 2023-02-23 2025-06-10 한양대학교 산학협력단 신규한 아미노락톤 유도체 및 이의 신규한 제조방법
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN121752566A (zh) * 2023-06-16 2026-03-27 中山优理生物医药有限公司 一种氨基吡啶类化合物、其制备方法、包含其药物组合物及其应用
WO2025016323A1 (zh) 2023-07-14 2025-01-23 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
AU2024320474A1 (en) 2023-08-08 2026-03-26 Mirati Therapeutics, Inc. Methods and compositions for treating malignant peripheral nerve sheath tumors
AU2024319888A1 (en) * 2023-08-09 2026-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Heteroaryl compound, preparation method therefor, and use thereof in medicine
WO2025059579A1 (en) 2023-09-15 2025-03-20 Ideaya Biosciences, Inc. Methods of treating mat2a related diseases
WO2025064286A1 (en) * 2023-09-19 2025-03-27 Mirati Therapeutics, Inc. Stable 4-(aminomethyl)-6-(phenylpyrazolyl)phthalazinone compositions and processes for preparation thereof
AU2024344078A1 (en) 2023-09-20 2026-04-02 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
WO2025061102A1 (zh) * 2023-09-20 2025-03-27 西藏海思科制药有限公司 一种含氰基的杂环化合物及其用途
WO2025072544A1 (en) 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025068985A1 (en) * 2023-09-28 2025-04-03 Beigene Switzerland Gmbh 1-(1-oxo-1,2-dihydrophthalazin-6-yl)cycloalkyl-1-carboxamide derivatives as mta-cooperative inhibitors of prmt5
TW202532064A (zh) * 2023-11-28 2025-08-16 大陸商正大天晴藥業集團股份有限公司 含有雜環二氫酞嗪的化合物
WO2025180390A1 (zh) * 2024-02-27 2025-09-04 烨辉医药科技(上海)有限公司 具有四环并环结构的mta协同性prmt5抑制剂化合物
WO2025212574A1 (en) 2024-04-02 2025-10-09 Mirati Therapeutics, Inc. Processes for preparation of prmt5 inhibitors and intermediates for making the same
WO2025217008A1 (en) 2024-04-08 2025-10-16 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer
US20250312343A1 (en) 2024-04-08 2025-10-09 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer
WO2025217007A1 (en) 2024-04-08 2025-10-16 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006285A1 (en) 2000-07-17 2002-01-24 Merck Sharp & Dohme Limited Imidazolophthalazine derivatives as ligands for gabaa receptors
JP2005501085A (ja) 2001-08-07 2005-01-13 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害剤として活性なアミノフタラジノン誘導体、それらを調製する方法およびそれらを含有する薬剤組成物
WO2017153518A1 (en) 2016-03-09 2017-09-14 Ctxt Pty Limited Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919351B2 (en) * 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
TW202122387A (zh) * 2019-09-12 2021-06-16 美商米瑞替療法公司 Mta協同性之prmt5抑制劑

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006285A1 (en) 2000-07-17 2002-01-24 Merck Sharp & Dohme Limited Imidazolophthalazine derivatives as ligands for gabaa receptors
JP2005501085A (ja) 2001-08-07 2005-01-13 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害剤として活性なアミノフタラジノン誘導体、それらを調製する方法およびそれらを含有する薬剤組成物
WO2017153518A1 (en) 2016-03-09 2017-09-14 Ctxt Pty Limited Prmt5 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Mackanova, M.; Vanags, G.，1-Aminomethyl-4-phthalazone，Zhurnal Obshchei Khimii，1958年，28，2798-2801
Mahmoud, Mahmoud R. et al.，Synthesis and spectral characterisation of some phthalazinone derivatives，Journal of Chemical Research，2012年，36(2)，75-82
Puodzhyunas, A. S. et al.，Phthalazine and heterocycles related to it XI. Derivatives of 4-(aminomethyl)-1-phthalazone，Pharmaceutical Chemistry Journal，1973年，7，566-570

Also Published As

Publication number Publication date
IL313281A (en) 2024-08-01
IL290341B1 (en) 2024-07-01
IL290341B2 (en) 2024-11-01
CN114728912A (zh) 2022-07-08
CL2022000603A1 (es) 2023-01-27
NO20220309A1 (en) 2022-03-11
BR112022004248A2 (pt) 2022-05-31
CO2022004513A2 (es) 2022-06-21
US11479551B2 (en) 2022-10-25
WO2021050915A1 (en) 2021-03-18
IL313281B1 (en) 2026-03-01
PH12022550399A1 (en) 2023-03-13
US20210078994A1 (en) 2021-03-18
US11492351B2 (en) 2022-11-08
AU2020345899B2 (en) 2026-03-12
CA3150515A1 (en) 2021-03-18
JP2022548255A (ja) 2022-11-17
IL290341A (en) 2022-04-01
AU2020345899A1 (en) 2022-03-03
TW202122387A (zh) 2021-06-16
US20210079003A1 (en) 2021-03-18
US20230054883A1 (en) 2023-02-23
MX2022002938A (es) 2022-05-26
CN120208880A (zh) 2025-06-27
SA522431915B1 (ar) 2025-06-12
EP4028388A1 (en) 2022-07-20
KR20220083691A (ko) 2022-06-20

Similar Documents

Publication Publication Date Title
JP7789662B2 (ja) Ｍｔａ協働ｐｒｍｔ５阻害剤
WO2022192745A1 (en) Mta-cooperative prmt5 inhibitors
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
AU2018267545B2 (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
EP2789615B1 (en) Azaindazoles as Btk kinase modulators and use thereof
WO2023278564A1 (en) Aminopyridine-based mta-cooperative prmt5 inhibitors
CA3089639C (en) Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors
AU2022330732A1 (en) Sos1 inhibitor and use thereof
AU2019289222B2 (en) Pyrazole derivatives as MALT1 inhibitors
WO2018119036A1 (en) Pyrazole derivatives as malt1 inhibitors
NO324843B1 (no) Substituerte pyrrolpyridinonderivater nyttige som fosfordiesterase-inhibitorer, og farmasoytiske preparater som innbefatter slike
JP2024542145A (ja) Ｐｒｍｔ５阻害剤としての２－アミノイミダゾール誘導体
AU2004236014A1 (en) Substituted-1-phthalazinamines as VR-1 antagonists
EA048673B1 (ru) Mta-кооперативные ингибиторы prmt5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241202

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251210

R150 Certificate of patent or registration of utility model

Ref document number: 7789662

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150